Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JSOM Welcomes Continued Insurance Coverage of Kampo Medicines
January 11, 2010
- Switchover from Tamoxifen to Aromasin Effective: Pfizer
January 11, 2010
- Januvia Ranked No. 1 in Both HP, GP Markets: Rep Track Survey
January 11, 2010
- New-Type Flu Vaccines from GSK, Novartis Recommended for Approval
January 11, 2010
- Increased Dose of Fulvestrant Reduces Risk of Breast Cancer Progression: AZ
January 11, 2010
- R&D Investment in Pharma Industry Up 3.3% in FY2008
January 11, 2010
- Solvay Applies for Pancreatic Enzyme Replacement Therapy
January 11, 2010
- 6 Medical Devices Recommended for Approval
January 11, 2010
- Janssen Introduces Business Units for Sales & Marketing
January 11, 2010
- Fulvestrant Applied for Postmenopausal Breast Cancer
January 11, 2010
- 5,032 Applicants for 16th Examination for MR Certification
January 11, 2010
- AFM to Manage Supply of All Drugs to Hospitals
January 11, 2010
- Tamiflu Approved for Prevention in Infants, Children
January 11, 2010
- Korosho to Reallocate Increased Medical Fees
January 11, 2010
- Kowa to Copromote Livalo with Lilly in the US
January 11, 2010
- Bup-4 Approved for Problems Associated with OAB
January 11, 2010
- Only 10% of Consumers Fail to Buy Class 1 OTC Drugs due to Absence of Pharmacists
January 11, 2010
- Ranbaxy to Market Olmesartan in 6 African Countries
January 11, 2010
- Pricing System Reform to Trigger Industry Reorganization
January 11, 2010
- Aricept's Medicoeconomic Benefits Demonstrated
January 11, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…